About the Company
We do not have any company description for BRAINSTORM CELL THERAPEUTICS INC. at the moment.
Exchange
OTC
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on BRAINSTORM CELL THERAPEUTICS INC.
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q2 2025 Earnings Call Transcript
Q2 2025 Earnings Call Transcript August 14, 2025 Brainstorm Cell Therapeutics Inc. beats earnings expectations. Reported EPS is $-0.34, expectations were $-0.41. Operator: Greetings, and welcome to ...
Brainstorm Cell Therapeutics outlines readiness for Phase IIIb ALS trial as funding and regulatory developments shape next steps
Q2 2025 Management View Chaim Lebovits, President and CEO, reaffirmed that "our top priority is advancing NurOwn into our planned Phase IIIb clinical trial." The ENDURANCE trial is designed to confirm ...
BCLI: Focused on Initiation of Phase 3b ENDURANCE Trial of NurOwn® in ALS…
BCLI READ THE FULL BCLI RESEARCH REPORT Business Update Focused on Advancing NurOwn into Phase 3b ENDURANCE Trial BrainStorm ...
Brainstorm Cell Therapeutics Inc BCLI - Morningstar
BrainStorm Cell Therapeutics to Announce First Quarter Results and Provide a Corporate Update on May 15, 2025 PR Newswire May 7, 2025, 10:30:00 AM ...
BrainStorm Cell Therapeutics Inc.: BrainStorm Cell Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update
Conference call and webcast scheduled for 8:30 a.m. Eastern Time Today, Thursday, August 14, 2025 NEW YORK, Aug. 14, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics ...
Brainstorm Cell Therapeutics Inc. (BCLI) Q4 2024 Earnings Call ...
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q4 2024 Earnings Conference Call March 31, 2025 8:30 AM ETCompany ParticipantsMichael Wood - Investor ...
BrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial ...
Net loss per share for the third quarter ended September 30, 2024 and September 30, 2023 was $0.51 and $0.45, respectively. About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics and Pluri Partner to Support ... - Nasdaq
--BrainStorm Cell Therapeutics Inc., a leading developer of cellular therapies for neurodegenerative diseases, today announced that it has entered into a Memorandum of Understanding with Pluri Inc ...
BrainStorm Cell Therapeutics to Announce First Quarter Results and ...
--BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it will hold a conference call to update shareholders ...
Brainstorm Cell Therapeutics Inc BCLI - Morningstar
Review the current valuation for Brainstorm Cell Therapeutics Inc (BCLI:PINX) stock based on a yearly calendar providing PE ratios, cash flow, EBITDA and other company valuation information.
Similar Companies
Loading the latest forecasts...